About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Proton Therapy for Hodgkin Lymphoma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT00850200

Proton Therapy for Hodgkin Lymphoma

The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radia...

Lead sponsor: University of Florida•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Florida

3 treatment plans will be created to deliver between a total of 21-39.6 Gray (Gy)/Centigray Equivalents (CGE) to the planning target volume (PTV). 1. Proton Plan 2. Conventional Plan 3. Intensity Modulated Radiotherapy (IMRT) Plan The patient will then receive the radiation modality with the lowest percentage of the body receiving 4 Gy (V4Gy/CGE)

Age

6 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Confirmed "classic" Hodgkin lymphoma.
•Completed chemotherapy.

Exclusion Criteria

•Prior radiotherapy.
•Prior or concurrent cancer other than non-melanomatous skin cancer.

Related studies

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

RECRUITINGPhase 2

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

NCT07275216 · Classic Hodgkin Lymphoma

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 2

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

NCT06386315 · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, and more

RECRUITINGPhase 2

CAR T-cell Therapy in Patients With Renal Dysfunction

NCT05909059 · Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 31, 2019Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment20

Start dateAug 2009

Last updatedJan 31, 2019

Condition

Hodgkin Lymphoma

Locations shown

University of Florida Proton Therapy Institute

Jacksonville, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions